. Author manuscript; available in PMC: 2023 Jul 1.

Published in final edited form as: Adv Drug Deliv Rev. 2022 May 5;186:114316. doi: 10.1016/j.addr.2022.114316

Table 1.

RNA nanoparticles functionalized with different therapeutic agents for disease treatment.

Therapy type	Therapeutic group	Targeting group	Nanoparticle	Construction	Disease type	Ref
Small molecule drug	DOX	Annexin A2_apt	3WJ	Self-assembly	Ovarian cancer	[34]
	CPT	FA	3WJ	Self-assembly	Cancer	[29]
	PTX	EGFR_apt	4WJ	Self-assembly	TNBC	[28]
Therapeutic oligo	BRCAA1 siRNA	FA	3WJ	Self-assembly	Gastric cancer	[42]
	Survivin siRNA	FA/PSMAapt/EGFR_apt	3WJ & EV	Self-assembly	CRC, prostate and breast cancer	[33]
	BIRC5 siRNA	EGFR_apt	3WJ & EV	Self-assembly	NSCLC	[43]
	VEGF siRNA	N/A	siRNA nano ball/RAPSI	RCT	AMD, cancer	[44,45]
	USE1 siRNA	N/A	BRC	RCT	Lung cancer	[46]
	Anti-miR17	PSMA_apt	3WJ	Self-assembly	Prostate cancer	[38]
	Anti-miR21	EGFR_apt /CD133_apt /PSMA_apt	3WJ	Self-assembly	TNBC, prostate cancer	[35,38,47]
	Thrombin aptamer	N/A	2-helix RNA origami	RNA origami	Blood coagulation	[48]
Combination	PTX, miR122	GalNAc	6WJ	Self-assembly	HCC	[31]
	DGLA, D5D siRNA	EpCAM_apt	3WJ	Self-assembly	Colon and lung cancer	[49,50]
	TAM, MED1 siRNA	HER2apt	3WJ	Self-assembly	Breast cancer	[30]